Pharmsynthesis

Pharmsynthesis is a Russian pharmaceutical company specializing in the development and production of drugs for treatment of socially significant diseases such as tuberculosis, HIV infection, oncology, diabetes and hepatitis. The company has been on the pharmaceutical market since 1997; its plants are located in Irkutsk, Ussuriysk, Tyumen, Bratsk and St. Petersburg.

P/E

Net profit

P/B

Book value

Debts

Net debt

Yield

Growth potential

Report period	2019	2020	2021	2022	2023	Q3 24
End date of the reporting period
Capitalization, ₽
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Report period	2019	2020	2021	2022	2023	Q3 24 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
EPS

Report period	2019	2020	2021	2022	2023	Q3 24 TTM
P/E
E/P
P/B
P/S
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Report period	2019	2020	2021	2022	2023	Q3 24 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin

Ticker	Name	Type	Nominal value	ISIN	Price
LIFE:RM	Pharmsynthesis	Common share	RUB 5	RU000A0JR514	RUB 3.605

Date	Type	Note	Source
29.04.2025 10:00	Financial results	Reporting for 2024 under IFRS(presumably)	e-disclosure.ru

Pharmsynthesis news

31.10.2024

Pharmsintez's RAS loss for 9 months of 2024 amounted to ₽121.8 million, down 36.4% from ₽191.6 million in the previous year. Revenue declined 32.3% to ₽124 million against ₽183.1 million a year earlier.

Source:

e-disclosure.ru

02.08.2024

Pharmsintez's RAS loss for 6 months of 2024 amounted to ₽74.31 million, down 46.2% from ₽138 million in the previous year. Revenue declined 19.8% to ₽102.24 million from ₽127.53 million a year earlier.

Source:

e-disclosure.ru

07.05.2024

Pharmsintez's RAS loss for 3 months of 2024 amounted to ₽241.57 million, down 8.7% from ₽264.54 million in the previous year. Revenue declined 7.9% to ₽284.64 million from ₽309.09 million a year earlier.

Source:

e-disclosure.ru

11.04.2024

Pharmsintez's RAS loss for 2023 amounted to ₽241.57 million, down 8.7% from ₽264.54 million in the previous year. Revenue declined 8% to ₽284.4 million from ₽309.09 million a year earlier.

Source:

e-disclosure.ru

All Pharmsynthesis news

General information

Company name	Pharmsynthesis
Tags	#pharmacy, #innovations of the russia
Sector	Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals
Business address	Rossiyskaya Federaciya, Leningradskaya oblast, Vsevolozhskiy rayon
Mailing address	188663 Rossiyskaya Federaciya, Leningradskaya oblast, Vsevolozhskiy rayon, gorodskoy poselok Kuzmolovskiy, stanciya Kapitolovo, 134 str. 1
CEO	Prilezhaev Efim Aleksandrovich
Phone	329-80-80
Website	pharmsynthez.com
Information disclosure	e-disclosure.ru

Pharmsynthesis

Pharmsynthesis balance sheet

Pharmsynthesis cash flows

Pharmsynthesis multipliers

Pharmsynthesis profitability

Pharmsynthesis shares

Pharmsynthesis expected events